Clinical Trial Update: A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating an intra-patient escalation dosing regimen of IMCgp100 in advanced uveal melanoma has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveal Melanoma

Drugs mentioned

• IMCgp100 (tebentafusp)

Snippet

Sponsor: Immunocore Ltd | Conditions: Uveal Melanoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-09-01